Sohn Dae-Won
Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Seoul One-Heart CV Clinic, Seoul, Korea.
Korean Circ J. 2025 Feb;55(2):67-78. doi: 10.4070/kcj.2025.0005.
Recently, usage of the term 'heart failure with preserved ejection fraction (HFpEF)' has predominated over the term 'diastolic heart failure (DHF).' The term 'preserved ejection fraction' represents only one aspect of DHF and does not provide insight into the hemodynamic mechanism of heart failure. In heart failure with reduced ejection fraction (HFrEF), depressed ejection fraction is the independent determinant of prognosis regardless of etiology. However, in HFpEF, because the prognosis is predominantly determined by etiologies of HFpEF, results of the drug on the prognosis in the clinical trial cannot be interpreted as it is. Therefore, studies on patients with HFpEF should be restricted to patients with diastolic dysfunction and, effects of drugs should be focused on symptom improvement not survival benefit. One reason for the prevalent use of HFpEF over DHF is the complexity in assessing diastolic function. Current official recommendations for the evaluation of diastolic function are too complex to be widely applied in the patient enrollment in large clinical trials as well as not easily applicable in our daily clinical practice. Therefore, there is a clinical need for a simple and practical way of assessing diastolic function.
最近,“射血分数保留的心力衰竭(HFpEF)”这一术语的使用已超过“舒张性心力衰竭(DHF)”。“射血分数保留”仅代表DHF的一个方面,并未深入揭示心力衰竭的血流动力学机制。在射血分数降低的心力衰竭(HFrEF)中,无论病因如何,射血分数降低都是预后的独立决定因素。然而,在HFpEF中,由于预后主要由HFpEF的病因决定,因此临床试验中药物对预后的结果不能直接解读。所以,对HFpEF患者的研究应限于舒张功能障碍患者,并且药物的作用应侧重于症状改善而非生存获益。HFpEF比DHF更常被使用的一个原因是评估舒张功能存在复杂性。目前关于舒张功能评估的官方建议过于复杂,难以在大型临床试验的患者入组中广泛应用,在日常临床实践中也不易应用。因此,临床上需要一种简单实用的舒张功能评估方法。